Market Overview

4 Reasons You Can Expect Allscripts To Outperform

Share:
4 Reasons You Can Expect Allscripts To Outperform
Related MCK
Opinion: Cardinal Health's Rising Dividends Make It Attractive
Jim Cramer Weighs In On McKesson, Mazor And MGM Growth Properties
Cost of U.S. opioid epidemic tops $500B (Seeking Alpha)
Related MDRX
Lightning Round: Jim Cramer Gives His Opinion On Kratos Defense & Security Solutions, Nike And More
20 Biggest Mid-Day Gainers For Monday

Analysts at Cowen highlighted four reasons why investors should consider buying Allscripts Healthcare Solutions Inc (NASDAQ: MDRX). The firm's Charles Rhyee upgraded Allscripts' stock rating from Market Perform to Outperform with a price target raised from $13 to $16.

1. Improving Fundamentals

Allscripts has developed a reputation over the past few quarters of reporting consistent results that at least matched expectations if not came in higher than expected, Rhyee commented in his upgrade note. This has resulted in a reduction in volatility earnings as the company shifted its business more towards a recurring revenue model.

tipranks.png

2. EIS Acquisition

Allscripts' acquisition of McKesson Corporation (NYSE: MCK)'s Enterprise Information Solutions Business will prove to be complementary to its current offerings and add incremental revenue along with cost synergies to fuel growth.

3. Free Cash Flow

The healthcare company boasts a "strong" 9.3-percent free cash flow yield which is superior to the group average of 4.4 percent, the analyst also noted. This could result in incremental earnings from a share buyback program, debt repayment or further M&A deals. In fact, one year's worth of free cash flow alone could be up to 10 percent accretive to the company's adjusted EPS.

4. Attractive Multiple

Finally, the analyst's $16 price target implies the stock will trade at 20.9x on expected 2018 EPS of $0.76 as opposed to the current multiple of 16.3x and the group's average multiple of 27.5x.

At last check, shares of Allscripts were up 5.21 percent at $13.73.

Related Links:

7 Biggest Price Target Changes For Monday

Benzinga's Top Upgrades, Downgrades For September 11, 2017

Latest Ratings for MCK

DateFirmActionFromTo
Oct 2017Cowen & Co.UpgradesMarket PerformOutperform
Sep 2017RBC CapitalInitiates Coverage OnSector Perform
Sep 2017BairdUpgradesNeutralOutperform

View More Analyst Ratings for MCK
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas News Upgrades Health Care Price Target Top Stories Analyst Ratings Best of Benzinga

 

Related Articles (MDRX + MCK)

View Comments and Join the Discussion!

Partner Center